916210-02-1

Basic information

• Product Name: 2-Trifluoromethyl-isonicotinonitrile
• Synonyms: 2-Trifluoromethyl-isonicotinonitrile;2-(trifluoroMethyl)pyridine-4-carbonitrile;2-(Trifluoromethyl)pyridine-4-carbonitrile, 4-Cyano-2-(trifluoromethyl)pyridine
• CAS NO: 916210-02-1
• Molecular Formula: C₇H₃F₃N₂
• Molecular Weight: 172.11
• Mol File: 916210-02-1.mol

Chemical Properties

• Boiling Point: 186.4±35.0 °C(Predicted)
• Appearance: /
• Density: 1.37±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -2.80±0.20(Predicted)
• CAS DataBase Reference: 2-Trifluoromethyl-isonicotinonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Trifluoromethyl-isonicotinonitrile(916210-02-1)
• EPA Substance Registry System: 2-Trifluoromethyl-isonicotinonitrile(916210-02-1)

Safety Data

• Hazardous Substances Data: 916210-02-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Trifluoromethyl-isonicotinonitrile is used as a key intermediate for the synthesis of various pharmaceuticals, including antihypertensive and antitumor agents. Its strong electron-withdrawing properties contribute to the development of these therapeutic agents, enhancing their efficacy in treating specific medical conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Trifluoromethyl-isonicotinonitrile is utilized as a precursor in the production of agrochemical compounds. Its unique chemical properties allow for the creation of effective agents that address various agricultural needs, such as pest control and crop protection.
Used in Organic Synthesis:
2-Trifluoromethyl-isonicotinonitrile is employed as a reagent in the preparation of various heterocyclic compounds. Its electron-withdrawing nature facilitates the synthesis of complex organic molecules, which are essential in the development of new chemical entities with potential applications in various fields.
Safety Considerations:
It is important to handle 2-Trifluoromethyl-isonicotonitrile with caution, as it is classified as a hazardous substance. Proper safety protocols should be followed during its use to minimize risks associated with exposure, ensuring the safety of personnel and the environment.

InChI:InChI=1S/C7H3F3N2/c8-7(9,10)6-3-5(4-11)1-2-12-6/h1-3H

Upstream product

• 100-48-1 pyridine-4-carbonitrile 
• 2926-29-6 Langlois reagent 
• 557-21-1 zinc(II) cyanide 
• 131748-14-6 4-chloro-2-trifluoromethylpyridine 
• 170886-13-2 4-hydroxy-2-trifluoromethylpyridine 
• 10386-27-3 2-bromoisonicotinonitrile 
• 129946-88-9 Umemoto's reagent 
• 131747-41-6 2-(trifluoromethyl)-4-pyridinecarboxylic acid 
• 1019201-53-6 2-(trifluoromethyl)isonicotinoyl chloride 

Downstream Products

• 588702-68-5 2-trifluoromethyl-isonicotinic acid methyl ester 
• 131747-41-6 2-(trifluoromethyl)-4-pyridinecarboxylic acid 
• 916210-33-8 tert-butyl {[2-(trifluoromethyl)pyridin-4-yl]methyl}carbamate 

Relevant articles and documents

Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and in Vivo Activity of an Oxadiazole Series

The gene KCNT1 encodes the sodium-activated potassium channel KNa1.1 (Slack, Slo2.2). Variants in the KCNT1 gene induce a gain-of-function (GoF) phenotype in ionic currents and cause a spectrum of intractable neurological disorders in infants and children, including epilepsy of infancy with migrating focal seizures (EIMFS) and autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). Effective treatment options for KCNT1-related disease are absent, and novel therapies are urgently required. We describe the development of a novel class of oxadiazole KNa1.1 inhibitors, leading to the discovery of compound 31 that reduced seizures and interictal spikes in a mouse model of KCNT1 GoF.

KCNT1 INHIBITORS AND METHODS OF USE

The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

KCNT1 INHIBITORS AND METHODS OF USE

The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS

The present invention relates to compounds as defined herein, which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to therapies using these activators. In particular, the invention relates to these activator compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3',5-adenosine monophosphate (cAMP).

Trifluoromethylation process for bromo-pyridine and derivatives thereof

The invention belongs to the field of organic chemistry and relates to a trifluoromethylation process for bromo-pyridine and derivatives thereof. The process disclosed by the invention comprises the following steps: by taking a bromo-pyridine compound with a formula a structure as a raw material, performing trifluoromethylation under the action of a Maben reagent fluoro-S-( trifluoromethyl)-dibenzothiophene salt having a formula c structure, thereby obtaining the tirfluoromethylpyridine compound with a formula b structure. The structural formula is as shown in the specification. In the formula, X- is Bronst conjugate base, R is H or -CN or halogen or C1-C6 alkyl or C1-C6 alkoxy or -OH or -R1OH or COR2 or -CO2R3 or -CONR4 or -NR5R6; R1 is C1-C6 akyl; R2, R3 and R4 are identically or differently H or C1-C6 alkyl; and the R5 and R6 are identically or differently H or O or C1-C6 alkyl or C1-C6 alkoxy.

Trifluoromethylation of heterocycles in water at room temperature

Using a reaction medium containing nanoparticles consisting of commercially available TPGS-750-M in water, a combination of Langlois' reagent and t-BuOOH can be used to effect trifluoromethylation of several heterocyclic arrays, including heteroaromatics. These reactions take place at ambient temperatures, and the aqueous medium can be recycled.

PROCESS FOR THE PREPARATION OF 2-TRIFLUOROMETHYL ISONICOTINIC ACID AND ESTERS

The invention relates to a novel process for the preparation of 2- trifluoromethyl isonicotinic acid and esters of the formula I which involves a palladium catalysed carbonylation or cyanation step wherein R1 is hydrogen or Q1-6-alkyl. The 2-trifluoromethyl isonicotinic acid and esters of the formula I are versatile intermediates for the preparation of active pharmaceutical and agrochemical agents such as for instance TAAR 1 agonists of the formula III.

HETEROBICYCLIC METALLOPROTEASE INHIBITORS

The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP- 13 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP- 13 inhibitors.